Search

News What Did the Patent for the Synthesis of Highly Purified Trazodone Bring?

Trazodone is a modern antidepressant that is used in the treatment of various types of depression, including those accompanied by anxiety, sleep disorders, or sexual dysfunction. Angelini's invention, with patent protection valid until 2028, presents several methods for the preparation of purified trazodone, or trazodone hydrochloride, which guarantees high purity of this substance and a low content of unwanted residues.

Source: Depression and Anxiety 5. 10. 2020

News Early and effective treatment of PBC significantly reduced the need for liver transplantation due to this disease

Current European and Czech guidelines include obeticholic acid (OCA) as the only registered option for 2nd line treatment of primary biliary cholangitis (PBC). In the Czech Republic, it is approved as a center-specific treatment and was granted permanent reimbursement from public health insurance in May 2022. The use of OCA in the treatment of PBC was also addressed in a symposium that was part of the professional program at this year's XLIX. May Hepatology Days in Olomouc.

Source: Primary Biliary Cholangitis 23. 6. 2022

News How to Achieve Left Ventricular Reverse Remodeling and Improve Outcomes in Heart Failure? Summary from HFA ESC Webinar

The current treatment algorithm for chronic heart failure with reduced ejection fraction (HFrEF) is well-known to clinicians. But how was its current form developed, and does it have the potential to change in the future? Experts discussed this and more at a web symposium on reverse remodeling sponsored by Novartis during the Heart Failure Association of the European Society of Cardiology (HFA ESC) congress. Notable presenters included HFA ESC President Professor Petar Seferovic and Professor Carolyn Lam from the National Heart Centre in Singapore.

Source: Chronic Heart Failure and Lipidology 16. 9. 2020

News Three tests to confirm the diagnosis of acquired hemophilia –⁠ infographic

Acquired hemophilia (AHA) typically manifests with spontaneous bleeding in patients with no prior personal history of significant bleeding.^1–4 The cause of the bleeding is a significant decrease in FVIII activity induced by autoantibodies against coagulation factor VIII.⁵ In polymorbid patients, established antithrombotic therapy at the time of AHA diagnosis may also contribute to the bleeding.⁴

Source: Acquired Hemophilia 8. 6. 2022

News Postoperative Wound Healing

Postoperative wound healing requires sufficient attention to prevent the development of complications that could impair the final functional and aesthetic outcome. This article aims to highlight important aspects of postoperative wound care.

Source: Wound Healing 3. 9. 2020

News Current View on Prophylactic Negative Pressure Wound Therapy in Practice from Surgeons' Perspective

The journal Updates in Surgery recently published the results of a survey on prophylactic negative-pressure wound therapy (pNPWT) conducted among Swiss surgeons. The survey results show how often this therapy is used, in what situations it is typically applied, and what could make negative-pressure wound therapy more attractive in the future.

Source: Wound Healing 17. 6. 2022

News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery

Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.

Source: Life-threatening Bleeding 20. 5. 2022

News Absorption of Levothyroxine: What Has the New Formulation of LT4-Containing Medicinal Products Brought?

Lifelong use of levothyroxine (LT4) is the cornerstone of hypothyroidism treatment. The narrow therapeutic range of LT4 places increased emphasis on accurate dosing and appropriate titration, making the introduction of new LT4 formulations with more precise active ingredient dosing and higher levels of bioequivalence a pathway to facilitate LT4 titration and improve patient adherence.

Source: Thyroid Disorders 26. 4. 2023

News Benefit of Short-term Androgen-deprivation Therapy Added to Radiotherapy of Localized Prostate Cancer for Long-term Survival

Androgen-deprivation therapy is associated with several adverse effects that also affect quality of life or increase the risks of serious age-related health problems. An extensive study focused on the benefits of short-term administration of androgen-deprivation therapy as an adjunct to radiotherapy in patients with prostate cancer and monitored its long-term impact on survival and the rate of late treatment toxicity.

Source: Oncological Treatment 26. 10. 2023

Články časopisu Case history acquired haemophilia A

Author of the article: Z. Čermáková, R. Hrdličková, Š. Blahutová, A. Ligová Source: Vnitřní lékařství | 4/2013 1. 4. 2013

News XR vs. IR Form of Metformin −⁠ It’s Not Just About Gastrointestinal Tolerability

It is well known that the XR form of metformin shows better gastrointestinal tolerability. However, research suggests that the two forms of metformin −⁠ XR and IR −⁠ differ in other aspects as well. In what ways? We will attempt to summarize this in the following text.

Source: Modern Treatment of Diabetes 16. 9. 2022

News Impact of Combined Oral Contraceptives on Body Weight

A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and 2 mg chlormadinone acetate (CMA) for 6 months, comparing the results between the two groups.

Source: Oral Contraception 10. 4. 2022

Články časopisu Are risk factors in prenatal and perinatal period important for develompent of schizophrenia?

Author of the article: P. Ambroz, J. Janoutová, O. Machaczka, M. Kovalová, A. Pohlídalová, K. Vařechová, O. Košta, H. Tomášková, O. Šerý, L. Hosák, V. Janout Source: Česká gynekologie | 1/2017 20. 1. 2017

News Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction

Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI) through sacubitril/valsartan reduces cardiovascular (CV) mortality and the risk of hospitalization for heart failure. The same benefit has also been demonstrated with the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), also known as gliflozins. A pre-specified sub-analysis of the EMPEROR-Reduced study evaluated whether the benefit of SGLT2i is also significant in patients treated with ARNI.

Source: Heart Failure 13. 7. 2022

News A Brief History of Deep Vein Thrombosis Treatment –⁠ From Antiquity to the Present

Deep vein thrombosis is among the common diseases that have accompanied humanity since its inception. Due to the low specificity of its clinical presentation (in contrast to, for example, varicose veins of the lower limbs), however, the disease long went undescribed in literature. The first descriptions of deep vein thrombosis did not appear until the Middle Ages –⁠ and from that moment, the gradual development of its treatment began. We offer you a brief but remarkable historical excursion in three stages.

Source: Prevention of Thrombosis in Surgery 4. 3. 2020